[ad_1]
The French government affirmed this Thursday that it would be “unacceptable” for the pharmaceutical group Sanofi to give priority to the United States. in case of finding a vaccine against covid-19, as indicated by a person in charge of the company.
“It would be unacceptable for us to have privileged access to this or that country under a pretext that it would be monetary,” French Secretary of State for the Economy Agnès Pannier-Runacher said in statements to the radio.
The director general of the French pharmaceutical group, Paul Hudson, said on Wednesday that if Sanofi found the vaccine against the disease, it would deliver it “first” to the United States, since this country “shares the risk” in seeking treatment in the framework of a collaboration with the Advanced Biomedical Research and Development Authority (BARDA).
The US government will have “the right to the largest orders”, since this country “has invested to try to protect its population”, The person in charge said in an interview with the Bloomberg agency.
He also specified that this progress could take place in a few days or weeks.
However, this Thursday, the director of Sanofi in France, Olivier Bogillot, assured that the group will not give priority to the United States in the distribution of a vaccine if the European Union (EU) is equally “effective” to finance its development.
“Americans are effective in this period. The EU has to be, too, helping us to make this vaccine available quickly, ”he asked.
Sanofi also specified in a statement that “Production on US soil would be primarily dedicated to the United States and the rest of (its) production capabilities would go to Europe, France and the rest of the world.”
The company also committed to making this possible vaccine “accessible to all.”
“Sanofi said that it would be accessible to all countries and I am satisfied. That vaccine should be a global public good“Estimated the French Minister of Higher Education, Research and Innovation, Frédérique Vidal, to the radio France Info.
“In the United States, there is always this species of national preference, which means that when there is an innovative product manufactured on its soil, there is a priority of distribution to the Americans,” said virologist Bruno Lina, member of the French scientific council.
“Production factories located in the United States will serve the United States and those outside the United States will serve the rest of the world,” he added.
[ad_2]
